Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 275 entries
View as:

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Phase: N/A Priority: Normal
NCT ID: NCT01653743 Org: User:
Start: 09/30/12 End: 12/31/14 Due: 12/31/15

A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily Practice

Phase: N/A Priority: Normal
NCT ID: NCT01112618 Org: User:
Start: 01/31/08 End: 02/28/11 Due: 02/28/12

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Phase: N/A Priority: Normal
NCT ID: NCT01514370 Org: User:
Start: 04/30/12 End: 03/31/16 Due: 03/31/17

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01134666 Org: User:
Start: 11/30/09 End: 08/05/14 Due: 08/05/15

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT01303237 Org: User:
Start: 02/28/11 End: 08/05/14 Due: 08/05/15

Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

Phase: N/A Priority: Normal
NCT ID: NCT01134627 Org: User:
Start: 02/28/06 End: 04/30/11 Due: 04/30/12

Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01388790 Org: User:
Start: 06/30/11 End: 05/31/13 Due: 05/31/14

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Phase: N/A Priority: Normal
NCT ID: NCT01075828 Org: User:
Start: 03/31/09 End: 07/31/14 Due: 07/31/15

A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

Phase: N/A Priority: Normal
NCT ID: NCT00504608 Org: User:
Start: 04/30/03 End: 04/30/04 Due: 04/30/05

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Phase: N/A Priority: Normal
NCT ID: NCT00122460 Org: User:
Start: 12/31/04 End: 01/31/11 Due: 01/31/12

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden

Phase: N/A Priority: Normal
NCT ID: NCT01307059 Org: User:
Start: 06/30/11 End: 12/31/15 Due: 12/31/16

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase: N/A Priority: Normal
NCT ID: NCT00865098 Org: User:
Start: 03/31/09 End: 06/30/10 Due: 06/30/11

Saizen® E-Device User Trial

Phase: N/A Priority: Normal
NCT ID: NCT00450190 Org: User:
Start: 02/28/06 End: 09/30/06 Due: 09/30/07

Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT01079988 Org: User:
Start: 02/29/04 End: 04/30/05 Due: 04/30/06

First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03261401 Org: User:
Start: 09/15/17 End: 06/14/19 Due: 06/14/20

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

Phase: N/A Priority: Normal
NCT ID: NCT01450319 Org: User:
Start: 12/31/11 End: 12/31/14 Due: 12/31/15

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00463788 Org: User:
Start: 06/30/07 End: 02/28/11 Due: 02/28/12

Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01510522 Org: User:
Start: 06/30/12 End: - Due: -

Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)

Phase: N/A Priority: Normal
NCT ID: NCT03566810 Org: User:
Start: 10/11/18 End: 11/28/18 Due: 11/28/19

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Phase: N/A Priority: Normal
NCT ID: NCT01423760 Org: User:
Start: 01/31/12 End: 08/31/15 Due: 08/31/16

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK

Phase: N/A Priority: Normal
NCT ID: NCT01263457 Org: User:
Start: 11/30/10 End: 12/31/15 Due: 12/31/16

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01988493 Org: User:
Start: 01/06/14 End: 12/03/20 Due: 12/03/21

ATRi Transition Rollover Study

Phase: N/A Priority: Normal
NCT ID: NCT03309150 Org: User:
Start: 01/10/18 End: 01/26/24 Due: 01/26/25

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Phase: N/A Priority: Normal
NCT ID: NCT03369665 Org: User:
Start: 06/20/18 End: 11/12/21 Due: 11/12/22

Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)

Phase: N/A Priority: Normal
NCT ID: NCT00249834 Org: User:
Start: 09/22/04 End: 01/16/06 Due: 01/16/07